FDA Approves New Indication for Gilotrif

Afatinib (Boehringer Ingelheim) gets a new indication for the first-line treatment of patients with metastatic ...

JANUARY 18, 2018

Afatinib Improved Outcomes Over Gefitinib for EGFR-mutated NSCLC

First-line afatinib significantly improved outcomes in EGFR-mutated NSCLC vs gefitinib.

APRIL 27, 2016